Upregulation of microRNA-204 inhibits cell proliferation, migration and invasion in human renal cell carcinoma cells by downregulating SOX4 | Zendy

Deyao Wu | Zendy; HUIXING PAN | Zendy; Yunfeng Zhou | Zendy; Zichun Zhang | Zendy; Ping Qü | Zendy; Jian Zhou | Zendy; Wanxiang Wang | Zendy

Open Access

Upregulation of microRNA-204 inhibits cell proliferation, migration and invasion in human renal cell carcinoma cells by downregulating SOX4

Author(s) -

Deyao Wu,

HUIXING PAN,

Yunfeng Zhou,

Zichun Zhang,

Ping Qü,

Jian Zhou,

Wanxiang Wang

Publication year - 2015

Publication title -

molecular medicine reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.727

H-Index - 56

eISSN - 1791-3004

pISSN - 1791-2997

DOI - 10.3892/mmr.2015.4259

Subject(s) - oncogene , cancer research , cell cycle , cell growth , cell , renal cell carcinoma , microrna , biology , mtt assay , clear cell renal cell carcinoma , cancer , transfection , cell culture , molecular medicine , gentamicin protection assay , metastasis , downregulation and upregulation , cell migration , pathology , medicine , biochemistry , genetics , gene

MicroRNA-204 (miR-204) has been reported to be frequently downregulated in various types of cancer, including renal, brain, ovary, hematological and colon cancer. The present study, investigated the effects of miR‑204 on renal cell carcinoma. Following transfection of miR‑204, an MTT assay, cell migration assay, cell invasion assay, western blot analysis and luciferase assay were performed in renal cell carcinoma cell lines. It was demonstrated that miR‑204 inhibits cell proliferation, migration and invasion in 786‑O and A498 cells. To the best of our knowledge, this study is the first to demonstrate that miR‑204 directly targets SOX4 in renal cell carcinoma. These results suggested that miR-204 may have value as a marker for the early detection of tumor metastasis and a therapeutic target preventing the invasion of renal cell carcinoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research